InsidersTradesSigma
Across 3 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Explore the complete record of transactions filed by Kelly Paul Edward, Director. Insider active across 1 company, notably Relmada Therapeutics, INC.. In total, 5 filings have been published. Split: 3 buys · 0 sell. Total volume traded: €308k. Activity tracked since 3 January 2022. The latest transaction was disclosed on 5 November 2025 (Acquisition). Regulator: SEC (Form 4). All data is free.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
5 of 5 declarations
Paul Edward Kelly is a Board Member of Relmada Therapeutics, Inc., a biotechnology company. As a board member, he participates in overseeing the company's activities and making strategic decisions. His expertise in the biotechnology field is valuable for guiding Relmada's initiatives.